These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33098154)

  • 61. Pictorial review on abdominal applications of ferumoxytol in MR imaging.
    Kordbacheh H; Baliyan V; Parakh A; Wojtkiewicz GR; Hedgire S; Harisinghani MG
    Abdom Radiol (NY); 2019 Oct; 44(10):3273-3284. PubMed ID: 31378828
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Incidental ferumoxytol artifacts in clinical brain MR imaging.
    Bowser BA; Campeau NG; Carr CM; Diehn FE; McDonald JS; Miller GM; Kaufmann TJ
    Neuroradiology; 2016 Nov; 58(11):1087-1091. PubMed ID: 27704163
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial
.
    Macdougall IC; Strauss WE; Dahl NV; Bernard K; Li Z
    Clin Nephrol; 2019 Apr; 91(4):237-245. PubMed ID: 30802204
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Crossover comparison of ferumoxytol and gadobenate dimeglumine for abdominal MR-angiography at 3.0 tesla: Effects of contrast bolus length and flip angle.
    Schubert T; Motosugi U; Kinner S; Colgan TJ; Sharma SD; Hetzel S; Wells S; Campo CA; Reeder SB
    J Magn Reson Imaging; 2017 Jun; 45(6):1617-1626. PubMed ID: 27862577
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Relaxivity of Ferumoxytol at 1.5 T and 3.0 T.
    Knobloch G; Colgan T; Wiens CN; Wang X; Schubert T; Hernando D; Sharma SD; Reeder SB
    Invest Radiol; 2018 May; 53(5):257-263. PubMed ID: 29215401
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety of gadolinium-based contrast material in sickle cell disease.
    Dillman JR; Ellis JH; Cohan RH; Caoili EM; Hussain HK; Campbell AD; Strouse PJ
    J Magn Reson Imaging; 2011 Oct; 34(4):917-20. PubMed ID: 21769966
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Preventive Effect of Changing Contrast Media in Patients With A Prior Mild Immediate Hypersensitivity Reaction to Gadolinium-Based Contrast Agent.
    Ryoo CH; Choi YH; Cheon JE; Yoon SH; Kang HR; Park SJ; Lee W
    Invest Radiol; 2019 Oct; 54(10):633-637. PubMed ID: 31033674
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development program.
    Bernd H; De Kerviler E; Gaillard S; Bonnemain B
    Invest Radiol; 2009 Jun; 44(6):336-42. PubMed ID: 19661843
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ferumoxytol nanoparticle uptake in brain during acute neuroinflammation is cell-specific.
    McConnell HL; Schwartz DL; Richardson BE; Woltjer RL; Muldoon LL; Neuwelt EA
    Nanomedicine; 2016 Aug; 12(6):1535-42. PubMed ID: 27071335
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prospective Multicenter Study of the Safety of Gadoteridol in 6163 Patients.
    Cho SB; Lee AL; Chang HW; Kim KA; Yoo WJ; Yeom JA; Rho MH; Kim SJ; Lim YJ; Han M
    J Magn Reson Imaging; 2020 Mar; 51(3):861-868. PubMed ID: 31663202
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling.
    Yancy AD; Olzinski AR; Hu TC; Lenhard SC; Aravindhan K; Gruver SM; Jacobs PM; Willette RN; Jucker BM
    J Magn Reson Imaging; 2005 Apr; 21(4):432-42. PubMed ID: 15779033
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Off-label intrathecal use of gadobutrol: safety study and comparison of administration protocols.
    Halvorsen M; Edeklev CS; Fraser-Green J; Løvland G; Vatnehol SAS; Gjertsen Ø; Nedregaard B; Sletteberg R; Ringstad G; Eide PK
    Neuroradiology; 2021 Jan; 63(1):51-61. PubMed ID: 32803338
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Quantitative comparison of delayed ferumoxytol T
    Horváth A; Varallyay CG; Schwartz D; Toth GB; Netto JP; Barajas R; Várallyay P; Szidonya L; Firkins J; Youngers E; Fu R; Ambady P; Bogner P; Neuwelt EA
    Magn Reson Med; 2018 Jul; 80(1):224-230. PubMed ID: 29205477
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
    Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
    Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
    Woolen SA; Shankar PR; Gagnier JJ; MacEachern MP; Singer L; Davenport MS
    JAMA Intern Med; 2020 Feb; 180(2):223-230. PubMed ID: 31816007
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Assessment of rates of acute adverse reactions to gadobenate dimeglumine: review of more than 130,000 administrations in 7.5 years.
    Fakhran S; Alhilali L; Kale H; Kanal E
    AJR Am J Roentgenol; 2015 Apr; 204(4):703-6. PubMed ID: 25794059
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease.
    Schwenk MH
    Pharmacotherapy; 2010 Jan; 30(1):70-9. PubMed ID: 20030475
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Feasibility of islet magnetic resonance imaging using ferumoxytol in intraportal islet transplantation.
    Jin SM; Oh SH; Oh BJ; Shim W; Choi JM; Yoo D; Hwang YH; Lee JH; Lee DY; Kim JH
    Biomaterials; 2015 Jun; 52():272-80. PubMed ID: 25818433
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ferumoxytol vs. Gadolinium agents for contrast-enhanced MRI: Thoughts on evolving indications, risks, and benefits.
    Finn JP; Nguyen KL; Hu P
    J Magn Reson Imaging; 2017 Sep; 46(3):919-923. PubMed ID: 28160356
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.